Abstract
The gliptins, a new class of oral drugs for type 2 diabetes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levels of incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 305-310 |
| Number of pages | 6 |
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 75 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2008 |
Fingerprint
Dive into the research topics of 'What role will 'gliptins' play in glycemic control?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver